OTOF-related Auditory Neuropathy (Hearing Loss) (H93.3X9)
Otarmeni (lunsotogene parvec-cwha), formerly known as DB-OTO, is the first FDA-approved gene therapy designed to treat congenital hearing loss caused by mutations in the OTOF gene. Developed by Regeneron Pharmaceuticals, the therapy targets otoferlin-related auditory neuropathy, an ultra-rare inherited disorder in which inner ear hair cells can detect sound but cannot properly transmit auditory signals to the brain because of deficiency of the otoferlin protein. Otarmeni works by delivering a functional copy of the OTOF gene directly into the cochlea using an engineered adeno-associated viral (AAV) vector administered through intracochlear injection. Once expressed within cochlear inner hair cells, the restored otoferlin protein helps reestablish synaptic neurotransmission between sensory hair cells and the auditory nerve, potentially restoring hearing function. Clinical trial data demonstrated substantial hearing improvement in many treated children, including recovery of speech perception and responsiveness to soft sounds, representing a landmark advance in sensory gene therapy. The approval is considered historically significant because it marks one of the first successful in vivo gene therapies capable of restoring a complex sensory function in humans and establishes proof-of-concept for future gene therapies targeting inherited forms of blindness, deafness, and neurologic disease.
Causes
The etiology of otoferlin-related hearing loss involves inherited mutations in the OTOF gene, which encodes otoferlin, a calcium-sensitive protein essential for neurotransmitter release at the synapse between cochlear inner hair cells and auditory nerve fibers. The disorder is typically inherited in an autosomal recessive pattern, meaning affected individuals inherit pathogenic variants from both parents. Otoferlin plays a critical role in synaptic vesicle fusion and rapid auditory signal transmission within the inner ear. Mutations that impair otoferlin function disrupt communication between otherwise structurally intact sensory hair cells and the auditory nerve, resulting in auditory neuropathy spectrum disorder (ANSD). Unlike many forms of congenital deafness caused by hair cell degeneration, otoferlin-related hearing loss primarily reflects failure of synaptic signal transmission rather than inability to detect sound itself. Symptoms are usually present at birth or early infancy and may range from severe hearing impairment to profound congenital deafness.
Pathophysiology
The pathophysiology of otoferlin-related hearing loss centers on defective synaptic transmission between cochlear inner hair cells and the auditory nerve due to deficiency or dysfunction of the otoferlin protein. Under normal conditions, sound waves stimulate inner hair cells within the cochlea, leading to calcium-triggered fusion of neurotransmitter-containing synaptic vesicles with the presynaptic membrane. Otoferlin functions as a critical calcium sensor and mediator of this rapid vesicle exocytosis process, enabling precise transmission of auditory signals to spiral ganglion neurons and ultimately the brain. Mutations in the OTOF gene impair otoferlin function, disrupting neurotransmitter release despite preservation of hair cell structure and the ability to mechanically detect sound. As a result, auditory signals become poorly synchronized or fail to propagate effectively along the auditory nerve, producing auditory neuropathy spectrum disorder characterized by severe speech perception impairment and sensorineural hearing loss. Because the underlying defect is synaptic rather than structural destruction of the cochlea, restoration of functional otoferlin through gene therapy has the potential to recover auditory signaling and improve hearing outcomes.
Clinical features
The clinical features of otoferlin-related hearing loss typically present in infancy or early childhood as severe to profound congenital sensorineural hearing loss associated with auditory neuropathy spectrum disorder (ANSD). Affected children often fail newborn hearing screening despite structurally preserved cochlear outer hair cell function, leading to a characteristic pattern in which otoacoustic emissions may remain intact while auditory brainstem responses are absent or severely abnormal. Patients commonly demonstrate poor speech perception, delayed language development, reduced responsiveness to sound, and difficulty understanding speech even when environmental sounds may still be partially detected. Hearing impairment is usually bilateral and may appear disproportionate to the preservation of cochlear anatomy. Because the disorder primarily affects synaptic transmission between inner hair cells and the auditory nerve rather than mechanical sound detection itself, auditory signaling becomes desynchronized and inefficient. Without intervention, affected children may develop significant communication and developmental delays, although early diagnosis and treatment with hearing rehabilitation or gene therapy may substantially improve auditory and language outcomes.
Diagnosis
The diagnosis of otoferlin-related hearing loss is based on a combination of audiologic testing, electrophysiologic evaluation, and genetic analysis. Affected infants often fail newborn hearing screening, prompting further assessment with auditory brainstem response (ABR) testing, which typically reveals absent or severely abnormal neural responses despite preservation of otoacoustic emissions that indicate intact outer hair cell function. This dissociation is characteristic of auditory neuropathy spectrum disorder (ANSD). Comprehensive audiologic evaluation usually demonstrates bilateral severe to profound sensorineural hearing loss with impaired speech perception and abnormal auditory signal synchronization. Definitive diagnosis is established through genetic testing identifying pathogenic mutations in the OTOF gene. Additional imaging studies such as MRI or CT scanning may be performed to evaluate cochlear anatomy and auditory nerve integrity, particularly when considering cochlear implantation or gene therapy. Early recognition is critical because timely intervention can significantly influence language acquisition and long-term developmental outcomes.
Mechanism of action videos
Therapeutic area: Neurology